公开(公告)号：WO2006089651A3

公开(公告)日：2007-01-11

申请号：PCT/EP2006001248

申请日：2006-02-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  ROESSLER BERTHOLD

Inventor： ROESSLER BERTHOLD

IPC: A61K9/00 ,  A61K9/28 ,  A61K31/675

CPC classification number: A61K9/2866 ,  A61K9/2846 ,  A61K31/675

Abstract: The invention relates to trofosfamide-containing film-coated tablets for oral administration as well as a method for the production thereof.

Abstract translation: 本发明涉及氯乙环磷酰胺含有用于口服给药的以及用于它们的制备方法的膜包衣片。

公开(公告)号：WO2006002887A8

公开(公告)日：2006-06-08

申请号：PCT/EP2005006991

申请日：2005-06-29

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  ROESSLER BERTHOLD

Inventor： ROESSLER BERTHOLD

IPC: A61K9/08 ,  A61K31/4439 ,  A61K47/12

CPC classification number: A61K47/12

Abstract: The invention relates to a pharmaceutical presentation form for the oral administration of a poorly soluble active compound (D-24 851; INN: indibulin) in the form of an aqueous drink solution, and a method for its preparation.

Abstract translation: 本发明涉及以饮用水溶液形式口服不溶性活性化合物（D-24 851; INN：靛蓝）的药物呈递形式及其制备方法。

公开(公告)号：WO2006133835A3

公开(公告)日：2007-07-19

申请号：PCT/EP2006005423

申请日：2006-06-07

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  ROESSLER BERTHOLD ,  RAAB GERHARD ,  REISSMANN THOMAS

Inventor： ROESSLER BERTHOLD ,  RAAB GERHARD ,  REISSMANN THOMAS

IPC: A61K9/16 ,  A61K31/4439

CPC classification number: A61K9/1623 ,  A61K9/1652 ,  A61K31/4439

Abstract: The present invention relates to a pharmaceutical formulation for oral administration of the poorly soluble and therefore hardly bioavailable tubulin inhibitor Indibulin and a process for its manufacture. In particular, there is provided a pharmaceutical formulation of lndibulin for oral administration comprising a granulate containing micronized lndibulin having a particle size of less than 20 µm for at least 99 vol.-% of the particles, at least one hydrophilic surfactant, and one or more capsulation excipients.

Abstract translation: 本发明涉及一种用于口服给予难溶性且因此难以生物利用的微管蛋白抑制剂靛敏素的药物制剂及其制备方法。 特别地，提供了用于口服给药的依地普林的药物制剂，其包含含有至少99体积％的颗粒，至少一种亲水性表面活性剂和至少一种亲水性表面活性剂的粒径小于20μm的微粉化丝氨酸的颗粒，以及一种或 更多的胶囊赋形剂。

公开(公告)号：CA2598759C

公开(公告)日：2013-08-06

申请号：CA2598759

申请日：2006-02-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K9/00 ,  A61K9/28 ,  A61K31/675

Abstract: The invention relates to trofosfamide-containing film-coated tablets for oral administration as well as a method for the production thereof.

公开(公告)号：PT1853218E

公开(公告)日：2013-07-23

申请号：PT06706868

申请日：2006-02-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K9/00 ,  A61K9/28 ,  A61K31/675

公开(公告)号：CA2598759A1

公开(公告)日：2006-08-31

申请号：CA2598759

申请日：2006-02-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K9/00 ,  A61K9/28 ,  A61K31/675

公开(公告)号：DK1853218T3

公开(公告)日：2013-09-23

申请号：DK06706868

申请日：2006-02-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K9/00 ,  A61K9/28 ,  A61K31/675

公开(公告)号：PL1667655T3

公开(公告)日：2012-05-31

申请号：PL04789095

申请日：2004-09-28

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K9/08 ,  A61K9/19 ,  A61K31/185 ,  A61K31/66 ,  A61K31/675 ,  A61K45/06 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00

公开(公告)号：HK1091146A1

公开(公告)日：2007-01-12

申请号：HK06113073

申请日：2006-11-29

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： ROESSLER BERTHOLD

IPC: A61K20060101 ,  A61K9/08 ,  A61K9/19 ,  A61K31/185 ,  A61K31/66 ,  A61K31/675 ,  A61K45/06 ,  A61K47/20 ,  A61K47/26 ,  A61P20060101 ,  A61P35/00

公开(公告)号：AU2005304952A1

公开(公告)日：2006-05-18

申请号：AU2005304952

申请日：2005-11-03

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： KIPP JAMES E ,  ROESSLER BERTHOLD ,  DOTY MARK ,  PAPADOPOULOS PAVLOS

IPC: A61K31/404 ,  A61K9/00 ,  A61P35/00

Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.